# OnCo record paper-olympia-6-year-update-ann-oncol-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-olympia-6-year-update-ann-oncol-2026" ;
schema:name "Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial"@en ;
schema:description "The six-year OlympiA update: the year of olaparib still cut relapse by 35 percent and death by 28 percent, six-year survival was 87.5 versus 83.2 percent, there were fewer new BRCA-related breast and ovarian cancers, and no excess of leukaemia."@en ;
schema:url ;
schema:dateModified "2026-09-24"^^xsd:date ;
schema:citation , , ;
onco:tag "tnbc-evidence" ;
schema:sameAs ;
schema:datePublished "2026"^^xsd:gYear ;
schema:author "Garber JE, Cameron D, Campbell C, et al." ;
onco:related ;
onco:cancers , ;
onco:technologies ;
onco:targets ;
onco:drugs ;
onco:companies , ;
onco:terms , ;
onco:trials , ;
onco:people , ;
onco:journals .